Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a report released on Monday, August 4th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings of ($0.63) per share for the year, up from their previous forecast of ($0.71). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. Cantor Fitzgerald also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.24) EPS.

Several other research firms have also recently issued reports on GOSS. The Goldman Sachs Group raised their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, May 16th. Wedbush raised their target price on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Scotiabank assumed coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They issued a “sector outperform” rating and a $11.00 target price for the company.

Gossamer Bio Trading Down 8.3%

Gossamer Bio stock opened at $1.98 on Wednesday. The stock has a 50-day moving average price of $1.48 and a 200 day moving average price of $1.23. Gossamer Bio has a 52 week low of $0.66 and a 52 week high of $2.23. The stock has a market cap of $450.05 million, a PE ratio of -3.19 and a beta of 1.96. The company has a current ratio of 5.71, a quick ratio of 5.71 and a debt-to-equity ratio of 6.70.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative return on equity of 537.92% and a negative net margin of 344.81%. The company had revenue of $11.49 million during the quarter, compared to the consensus estimate of $4.12 million.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors and hedge funds have recently bought and sold shares of GOSS. Drive Wealth Management LLC grew its stake in shares of Gossamer Bio by 52.7% during the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after buying an additional 8,797 shares during the period. Graham Capital Management L.P. acquired a new position in Gossamer Bio in the fourth quarter valued at $32,000. Virtu Financial LLC purchased a new stake in Gossamer Bio during the first quarter valued at about $38,000. Fullcircle Wealth LLC acquired a new stake in Gossamer Bio during the fourth quarter worth about $43,000. Finally, Invesco Ltd. purchased a new position in shares of Gossamer Bio in the 1st quarter worth about $48,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.